首页> 外文期刊>Drug delivery. >Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles
【24h】

Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles

机译:叶酸修饰多西他赛负载人血清白蛋白纳米粒子的制备,表征和抗肿瘤活性

获取原文
       

摘要

Context: Docetaxel is now a major antitumor drug in clinical use for the treatment of a variety of tumors. The ethanol/Tween 80 solvent required in the formulation to increase the docetaxel solubility is at least partly responsible for the hypersensitivity reaction, decreased uptake by tumor tissue, and increased exposure to other body compartments.Objective: The present study was aimed at developing hydrosoluble DTX-FA-HSANPs targeting tumor cells and to investigate antitumor activities of the nanoparticles.Materials and methods: The DTX-HSANPs were prepared using a desolvation technique and the carboxylic groups of NHS-folate were conjugated with the amino groups of the human serum albumin nanoparticles, and studied their size and zeta potential, drug loading efficiency, surface morphology, release properties in vitro, and antitumor activities.Results: The spherical nanoparticles obtained were negatively charged with a zeta potential of about ?30?mV and characterized around 150?nm with a narrow size distribution. Drug loading efficiency was approximately 17.2%. The folate-decorated nanoparticles targeted a human hepatoma cell line effectively. The in vitro drug release of DTX-FA-HSANPs in the first 96?h corresponded with the following equation: Q?=?18.87851???0.13866t?+?0.21276t2???0.00704t3?+?0.0000847854t4???0.00000034991t5 (R2?=?0.98155). Moreover, the in vitro antitumor activities of DTX-FA-HSANPs were close to the activities of the positive control (docetaxel). The in vivo inhibition ratios of DTX-FA-HSANPs and docetaxel were 66.2% and 59.5%, respectively, at a dose of 5?mg/kg.Discussion and conclusion: In light of the observed antitumor activities, it would be of considerable interest to collect sufficient data for the clinical application of docetaxel-loaded nanoparticles.
机译:背景:多西他赛现在是临床上用于治疗多种肿瘤的主要抗肿瘤药物。制剂中增加多西紫杉醇溶解度所需的乙醇/吐温80溶剂至少部分负责超敏反应,肿瘤组织摄取减少以及与其他机体的接触增加。目的:本研究旨在开发水溶性DTX -FA-HSANPs靶向肿瘤细胞并研究纳米颗粒的抗肿瘤活性。材料和方法:DST-HSANPs用去溶剂化技术制备,NHS-叶酸的羧基与人血清白蛋白纳米颗粒的氨基缀合。结果:获得的球形纳米粒子带负电,ζ电势约为?30?mV,并具有约150?nm的特性,并对其进行了研究。具有狭窄的尺寸分布。载药效率约为17.2%。叶酸修饰的纳米颗粒有效地靶向人肝癌细胞系。 DTX-FA-HSANPs在最初96小时内的体外药物释放与以下方程式相对应:Q≥=?18.87851 ??? 0.13866t?+?0.21276t 2? ?? 0.00704 t 3 ?+?0.0000847854t 4? ?? 0.00000034991t 5 (R 2? =?0.98155) 。此外,DTX-FA-HSANP的体外抗肿瘤活性接近阳性对照(多西他赛)的活性。剂量为5?mg / kg时,DTX-FA-HSANP和多西他赛的体内抑制率分别为66.2%和59.5%。讨论和结论:鉴于观察到的抗肿瘤活性,将引起广泛关注收集足够的数据用于多西他赛负载纳米颗粒的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号